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The Journal of Immunology
Targeting Neutrophilic Inflammation Using
Polymersome-Mediated Cellular Delivery
James D. Robertson,*,†,‡ Jon R. Ward,†,‡ Milagros Avila-Olias,* Giuseppe Battaglia,x,{,1 and
Stephen A. Renshaw†,‡,1
Neutrophils are key effector cells in inflammation and play an important role in neutralizing invading pathogens. During inflam-
mation resolution, neutrophils undergo apoptosis before they are removed by macrophages, but if apoptosis is delayed, neutrophils
can cause extensive tissue damage and chronic disease. Promotion of neutrophil apoptosis is a potential therapeutic approach for
treating persistent inflammation, yet neutrophils have proven difficult cells to manipulate experimentally. In this study, we deliver
therapeutic compounds to neutrophils using biocompatible, nanometer-sized synthetic vesicles, or polymersomes, which are inter-
nalized by binding to scavenger receptors and subsequently escape the early endosome through a pH-triggered disassembly mech-
anism. This allows polymersomes to deliver molecules into the cell cytosol of neutrophils without causing cellular activation. After
optimizing polymersome size, we show that polymersomes can deliver the cyclin-dependent kinase inhibitor (R)-roscovitine into
human neutrophils to promote apoptosis in vitro. Finally, using a transgenic zebrafish model, we show that encapsulated (R)-
roscovitine can speed up inflammation resolution in vivo more efficiently than the free drug. These results show that polymersomes
are effective intracellular carriers for drug delivery into neutrophils. This has important consequences for the study of neutrophil
biology and the development of neutrophil-targeted therapeutics. The Journal of Immunology, 2017, 198: 3596–3604.
N
eutrophils are the most abundant leukocyte in mammals
and are the first cells recruited to sites of infection. The
main role of neutrophils is to remove microorganisms
through phagocytosis (1). Internalized microorganisms are rapidly
degraded in the phagosome using a destructive mixture of prote-
ases, antimicrobial peptides, and reactive oxygen species, which
are delivered by cytoplasmic granules (2). Killing pathogens in-
tracellularly allows neutrophils to remove microorganisms without
causing off-target damage to the host; however, not all microor-
ganisms can be removed by this method, particularly if contact is
obstructed by the extracellular matrix (3). Following activation,
neutrophils degranulate, expelling their destructive contents into
the extracellular environment (4). This degranulation helps ensure
that the surrounding area is sterilized, and collapses nearby capil-
laries and lymphatic vessels to prevent microorganisms from es-
caping (3). Yet, unsurprisingly, degranulation can cause extensive
tissue damage, so this process must be tightly controlled. Therefore,
once an infection has been cleared, neutrophil apoptosis is an im-
portant step in preventing further damage to the host (5).
Neutrophil apoptosis can be initiated following phagocytosis of
target pathogens, or, in the absence of survival signals, it can occur
spontaneously (6). This ensures that neutrophils cease proin-
flammatory functions and allows their toxic contents to be pack-
aged within apoptotic bodies for safe clearance by macrophages.
Upregulation of phosphatidylserine and other “eat-me” signals
during apoptosis help ensure that neutrophil clearance occurs
before the contents are lost through secondary necrosis (7).
Not only does apoptosis prevent neutrophils from responding to
proinflammatory stimuli, but apoptotic neutrophils can also ac-
tively promote inflammation resolution by sequestering cytokines
(8) and converting macrophages to a proresolution phenotype
following efferocytosis (9). However, apoptosis can be delayed by
stimulation with survival factors such as GM-CSF, with prolonged
neutrophil survival leading to excessive tissue damage, as ob-
served in multiple inflammatory diseases (10–12).
Driving neutrophil apoptosis is a potential therapeutic strategy
for the treatment of inflammatory diseases. This can be achieved by
drug therapy with Tanshinone IIA or cyclin-dependent kinase
inhibitors (CDKi) (13). The broad spectrum CDKi (R)-roscovitine,
for instance, has emerged as a potent inducer of neutrophil apo-
ptosis (14–16) even in the presence of survival factors such as
GM-CSF (17). Drug delivery carriers may enable more efficient
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access to the neutrophil intracellular milieu to help encourage
drug signaling processes and limit off-target side effects. How-
ever, cellular delivery and genetic manipulation of neutrophils has
proven difficult. This has not only prevented us from manipulating
neutrophils for therapeutic intervention, but has also limited our
understanding of the molecular pathways that control neutrophil
function. A number of neutrophil transfection techniques have
been attempted, but none have become well established (18–21).
In this study PMPC-PDPA polymersomes are explored as drug
delivery vectors for neutrophils. Polymersomes were tested for
adverse effects on neutrophil viability and IL-8 release, and their
size was optimized for efficient cargo delivery. Finally, the ability
of polymersomes to encapsulate and deliver (R)-roscovitine into
neutrophils was tested in vitro and in a zebrafish model of neu-
trophilic inflammation.
Materials and Methods
Reagents
Unless otherwise stated, reagents were purchased from Sigma-Aldrich.
Chloroform and methanol were purchased from Fisher Scientific. (R)-
roscovitine was purchased from Cambridge Bioscience, GM-CSF from
PeproTech, and cascade blue from Life Technologies. The IL-8 ELISA kit
was purchased from R&D Systems.
Polymersome formation
Polymersomes were assembled using the pH-switch or film-rehydration
method as described previously (22). The synthesis of PMPC25-PDPA65
and rhodamine 6G-labeled PMPC25-PDPA70 was performed by reversible
addition fragmentation chain-transfer polymerization, and atom-transfer
radical polymerization respectively (23, 24). Polymersomes were puri-
fied using crossflow filtration and differential centrifugation as described
previously (25). Briefly, polymersomes were purified into different sizes by
initially extracting the smallest nanoparticles using a KrosFlo Research IIi
System with a 50 nm hollow fiber filter module, all purchased from
Spectrum Laboratories. This was followed by differential centrifugation at
increasingly higher centrifuge speeds (25).
Polymersome uptake by human neutrophils
Peripheral blood was extracted from healthy donors as approved by the
South Sheffield Research Ethics Committee (STH13927). Neutrophils were
purified from the peripheral blood of healthy donors using a Percoll density
gradient as described previously, typically yielding neutrophil purities of
.95% (26, 27). For cytospin apoptosis counts and cytokine ELISAs,
neutrophils were further purified using negative magnetic selection, to
ensure that contaminating PMBCs did not influence neutrophil responses
(28, 29). All other experiments on human neutrophils were using neutro-
phils purified using the Percoll gradient only. In the initial neutrophil vi-
ability and IL-8 ELISAs, polymersomes were not purified to a specific size
fraction. Viability was assessed either by observation of nuclear mor-
phology on histochemically stained cytospin preparations according to
well-accepted protocols (30), or by flow cytometry of neutrophils stained
with Alexa Fluor 647 annexin V and propidium iodide (BioLegend). Flow
cytometry was performed with a BD FACSArray Bioanalyzer with 10,000
events captured within the neutrophil gate. Data were analyzed using
FlowJo software (Tree Star, OR). This experiment was repeated with a
similar protocol on FaDus purchased from the American Type Culture
Collection (Manassas, VA), seeded in 24-well plates, and grown for 1 d in
supplemented DMEM.
Cytokine release was measured using an IL-8 ELISA using matched Ab
pairs at optimized concentrations as described previously (31). To assess the
delivery of polymersomes encapsulating rhodamine B octadecyl ester
perchlorate (rhodamine B), neutrophils were incubated with 1 mg/ml of
CelLuminate for 6 or 24 h, and then washed, fixed with 13 Cellfix (Becton
Dickinson) and visualized on a Perkin-Elmer UltraVIEW VoX spinning
disk confocal microscope with a 514 nm laser and a 403 oil immersion
lens.
Optimization of polymersome size
Purified polymersome size fractions were incubatedwith neutrophils at 37˚C
for the desired time period. Neutrophils were centrifuged at 300 RCF for
3 min with a table-top centrifuge (Eppendorf Minispin) and the pellet was
then washed with ice-cold PBS; this washing step was repeated. Neutro-
phils were kept on ice before the fluorescence intensity was measured
using an LSR II Flow Cytometer (BD Biosciences) with 10,000 events
captured within the neutrophil gate and a 450 nm violet laser (cascade
blue) or a 575 nm blue laser (Rho-PMPC-PDPA). The relative median
fluorescence intensity (rMFI) was obtained by dividing the MFI of the
treated neutrophils by the MFI of the untreated neutrophils and subtracting
one, so that an MFI value equal to the control had an rMFI of 0. Mi-
croscopy was undertaken on cells fixed with 13 Cellfix (Becton Dick-
inson) and visualized with a Perkin-Elmer UltraVIEW VoX spinning disk
confocal or an Olympus FV1000 confocal microscope.
Calculation of encapsulated (R)-roscovitine concentration
Following (R)-roscovitine encapsulation, free drug was removed using gel
permeation chromatography (32) and the polymersomes were purified to
the desired size as described above. To measure the concentration of
polymer and encapsulated (R)-roscovitine, reverse-phase HPLC (RP-
HPLC) was performed on a Dionex Ultimate 3000 system with an asso-
ciated ultraviolet-Vis spectrophotometer. The sample pH was lowered to
six using 1 M HCL to disassemble the polymersomes. The samples were
then passed through a C18 analytical column (Phenomenex Jupiter; 300 A˚,
1503 4.6 mm, 5 mm) and run in a multistep gradient of eluent a: methanol
+ 0.1% trifluoroacetic acid, and eluent b: H2O + 0.1% trifluoroacetic acid.
The gradient was as follows: 0 min 5%, 6.5 min 5%, 12 min 100%, 14 min
100%, 15 min 5%, 20 min 5%. RP-HPLC ultraviolet-Vis calibration curves
were used to calculate the concentration of polymer and encapsulated (R)-
roscovitine.
Zebrafish husbandry and assays
Zebrafish were raised and maintained according to standard protocols (33)
in U.K. Home Office-approved aquaria at the University of Sheffield
Zebrafish Facility in the Bateson Centre. The transgenic Tg(mpx:GFP)i114
line (mpx:GFP), was used in both zebrafish experiments. Injury by tail
fin transection was performed as previously described (34). Three days
postfertilization (dpf) mpx:GFP zebrafish embryos were immersed in 0.02% 3‐
amino benzoic acid ethyl ester (tricaine), then placed on masking tape on a
Petri dish lid. The embryos were injured by complete tail fin transection at
the caudal fin with a microscalpel (World Precision Instruments). Four
hours following injury, zebrafish were visualized under a fluorescent dis-
secting microscope (Leica MZ10F) and embryos with 20–25 neutrophils at
the injury site (posterior to the circulatory loop) were selected, transferred
to a 96-well plate and polymersomes or their controls were added to the
zebrafish media. Zebrafish were then washed and visualized using a
Perkin-Elmer UltraVIEW VoX spinning disk confocal microscope or the
number of neutrophils at the injury site was counted under a fluorescent
dissecting microscope.
Statistical analysis
Data were analyzed using a two-way ANOVA or a one-way ANOVAwith
Bonferroni posttest (Prism 5.0; GraphPad Software).
Results
Polymersomes are biocompatible intracellular vectors for
human neutrophils
In a similar manner to membrane phospholipids, the amphiphilic
PMPC-PDPA copolymer contains a hydrophilic group (PMPC) and
a hydrophobic group (PDPA), which enables the copolymer to self-
assemble into a membrane in aqueous solutions (35). We have
shown that these membranes wrap into vesicles, otherwise known
as polymersomes, which are capable of encapsulating a variety of
molecules, proteins, and nucleic acids (36–38). The DPA com-
ponent of this copolymer is a weak base with a pKa of 6.4 under
physiological conditions. Once internalized, polymersomes are
transported into early endosomes where the drop in pH triggers
polymersome disassembly, resulting in a sudden increase in the
number of charged molecules (39). This leads to an osmotic
shock, triggering temporary destabilization of the endosome and
release of some of the polymersome cargo into the cell cytosol
(38). Importantly, the pKa of the DPA group ensures this process
occurs very early on in the endolysosomal pathway, enabling
release of the polymersome cargo without provoking cellular
toxicity (39).
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The PMPC block is a biocompatible polymer that is highly re-
sistant to protein adhesion, and widely used as a coating for contact
lenses, coronary stents, and artificial joints (40–42). Although
PMPC-PDPA are resistant to unspecific protein adhesion, we have
shown previously that the phosphorylcholine groups have high af-
finity for scavenger receptor B1 enabling them to bind and become
internalized by a variety of cell types, particularly immune cells and
cancer cells, which are rich in scavenger receptors (39, 43).
To explore the potential of PMPC-PDPA polymersomes as in-
tracellular delivery vectors for neutrophils, human peripheral blood
neutrophils were purified from the blood of healthy donors using a
Percoll density gradient and the cells were incubated with poly-
mersomes encapsulating the fluorescent dye rhodamine B. After
6 or 24 h incubation, the cells were washed then examined by
confocal microscopy, revealing delivered rhodamine was dispersed
throughout the interior of the cell (Fig. 1A, Supplemental Video 1).
Extensive toxicity analysis on over 20 different cell types has
demonstrated that PMPC-PDPA polymersomes are well tolerated,
even at relatively high concentrations (39). However, neutrophils
are very sensitive cells and many manipulations cause neutrophil
activation or cell death (26).
To ensure that polymersomes alone do not alter neutrophil life
span, the rate of neutrophil apoptosis after incubation with 1 mg/ml
of polymersomes for 4 or 20 h was measured by observation of
nuclear morphology on histochemically stained cytospin prepa-
rations according to well-accepted protocols (30). Treatment with
GM-CSF (0.01 mg/ml) resulted in a reduction in neutrophil apo-
ptosis at both time points, but empty polymersomes had no effect
A
B C D E
FIGURE 1. Uptake of polymersomes by human neutrophils. (A) Confocal photomicrograph of neutrophils incubated with polymersomes encapsulating
rhodamine B octadecyl ester perchlorate for 6 or 24 h at a final concentration of 1 mg/ml, scale bar, 8 mm. (B) Apoptosis assays on primary human
neutrophils after incubation with empty polymersomes or GM-CSF (0.01 mg/ml) for 4 h or (C) 20 h. (D) IL-8 levels assayed by ELISA on human
neutrophils after incubation with empty polymersomes or controls for 4 h or (E) 6 h. Neutrophils treated with polymersomes were not significantly different
from the negative control group in all experiments (one-way ANOVAwith a Bonferroni multiple comparison test, error bars = SEM from three independent
experiments, *p , 0.05, ***p , 0.001).
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on neutrophil apoptosis counts compared with the PBS control
(Fig. 1B, 1C).
Activation of neutrophils and initiation of their proinflammatory
response results in the production and release of inflammatory
cytokines such as IL-8 (44). IL-8 is a potent chemokine that is
involved in recruiting neutrophils and coordinating the immune
response. To determine the effect of polymersomes on neutrophil
activation, neutrophils were incubated with polymersomes for 4 or
6 h. Supernatants were extracted and IL-8 concentration was
measured by ELISA. Incubation with polymersomes at a concen-
tration of 1 mg/ml had no effect on neutrophil IL-8 release com-
pared with the PBS control (Fig. 1D, 1E). In contrast, the positive
control (LPS, LPS) activated neutrophils and increased the amount
of IL-8 release at both time points.
Optimizing polymersome size for efficient cargo delivery
Nanoparticle size is known to have a critical effect on numerous
aspects of the nanoparticle in vivo function including: circulation
time, cell binding, internalization, extravasation, and biodistribution
(45–47). Controlling the rate of internalization will influence both
the efficiency and specificity of a drug vector for a specific cell type.
However, the rate of internalization can be difficult to predict the-
oretically because it is also dependent on nanoparticle surface
chemistry (39), ligand surface density (48), receptor expression and
binding affinity (49), the mechanism(s) of receptor-mediated en-
docytosis (50), and even the degree of nanoparticle interactions on
the plasma membrane (51). Thus, the optimal nanoparticle size
depends on the specific surface properties of the nanoparticle and
the target cell (45), and must be determined experimentally.
Following endosomal release, polymersome-forming copoly-
mer chains integrate with cell membranes (39). As shown in
Supplemental Fig. 1A, neutrophils incubated with rhodamine-
labeled polymersomes (where rhodamine is covently bound to
individual copolymer chains) show a strong signal from mem-
branous compartments (Supplemental Fig. 1A). The amino-
coumarin fluorophore cascade blue is a water-soluble, cell-
impermeable fluorescent dye often used to measure membrane
permeability (52). When polymersomes loaded with cascade blue
were incubated with neutrophils, the signal was distributed
throughout the cell cytosol (Supplemental Fig. 1A). To investigate
the consequence of polymersome size on internalization by human
neutrophils, rhodamine-labeled polymersomes encapsulating cas-
cade blue were formed by the pH-switch method. By encapsu-
lating cascade blue in rhodamine-labeled polymersomes, it was
possible to track the amount of polymer internalized by the cell, as
well as the amount of delivered cargo.
Rhodamine-labeled polymersomes encapsulating cascade blue
were separated into six size fractions using crossflow filtration
followed by differential centrifugation as described previously
(25). The concentration of cascade blue and rhodamine-labeled
polymer was measured using fluorescence spectroscopy. Human
neutrophils were incubated with one of the six purified polymer-
some size fractions at a final polymer concentration of 0.1 mg/ml.
At multiple time points throughout the experiment, neutrophils
were analyzed by flow cytometry. Example dot plots are shown in
Supplemental Fig. 1B.
Incubation with polymersomes resulted in a rapid increase in the
normalized neutrophil fluorescence intensity, referred to as the
rMFI. The degree of neutrophil fluorescence over time was de-
pendent on the polymersome size (Fig. 2A, 2B). Neutrophils
treated with the 190 nm polymersome fraction appeared to have
the highest internalization of rhodamine labeled polymer and
cascade blue. By plotting the data from the final time point only, it
can be seen that the amount of polymer internalized by neutrophils
escalates with increasing diameters up to 190 nm (Fig. 2C). This is
consistent with previous reports showing that spherical nano-
particle uptake is optimal at a given critical radius, which depends
on the receptor/ligand affinity and receptor density (53).
To investigate the rate at which the polymersome signal drops
from neutrophils following internalization, neutrophils were in-
FIGURE 2. Quantified neutrophil rMFI
over time after incubation with rhodamine-
labeled polymersomes encapsulating cascade
blue. (A) Neutrophil rMFI in the rhodamine
channel showing the amount of rhodamine-
labeled polymer internalized over time for
each of the size fractions. (B) Neutrophil
rMFI in the cascade blue channel showing
the amount of cascade blue delivered into
neutrophils over time for each size fraction.
The graphs show that neutrophil fluorescence
from the polymer and cascade blue increases
over time with a plateau at later time points.
The extent of neutrophil fluorescence was
dependent on the polymersome size. (C)
Neutrophil rMFI after incubation with poly-
mersomes at each size fraction for 600 min.
(D) rMFI of neutrophils treated with rhodamine-
labeled polymersomes and washed after 240
min to determine the rate of polymer release
(on all graphs error bars = SEM, from three
independent experiments).
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cubated with 190 nm polymersomes using the same protocol. After
240 min the neutrophils were pelleted by centrifugation, washed,
and returned to normal media. The neutrophil rMFI was measured
at three further time points to determine the rate of polymer release
from the cells. Interestingly, once the extracellular polymersomes
were removed, neutrophil rMFI rapidly decreased (Fig. 2D). This
may be due to polymer metabolism or secretion.
The uptake of polymersomes in vivo will depend not only on the
rate of internalization by neutrophils at a given nanoparticle size,
but also the relative rate of internalization by other cell types.
Therefore, the size-dependent internalization experiment was re-
peated using the cell line FaDu for comparison. Once again, FaDu
cells were incubated with one of six purified polymersome size
fractions and analyzed by flow cytometry at multiple time points up
to 25 h. In agreement with the complementary neutrophil exper-
iment, the fluorescence from both the cascade blue channel and the
rhodamine channel increased over time and then plateaued
(Supplemental Fig. 2A, 2B). However, the effect of size on in-
ternalization was far less marked (Supplemental Fig. 2C).
Encapsulated (R)-roscovitine promotes neutrophil apoptosis
The broad spectrum CDKi (R)-roscovitine drives neutrophil ap-
optosis by downregulating the survival protein Mcl-1 (14); how-
ever, clinical use may be restricted due to off-target effects on
non-immune cell populations. To overcome this potential limita-
tion, (R)-roscovitine was encapsulated within polymersomes using
the film rehydration method (54). Following (R)-roscovitine en-
capsulation, polymersomes were purified to a mean diameter of
∼200 nm (Supplemental Fig. 3A). Encapsulation of (R)-
roscovitine was calculated by RP-HPLC associated with ultravi-
olet detection (Supplemental Fig. 3B, 3C).
Human neutrophils were incubated for 8 h with GM-CSF (0.01
mg/ml) and 1–30 mM of encapsulated (R)-roscovitine or free (R)-
roscovitine. Cell viability was measured by flow cytometry with
annexin V and propidium iodide staining. Incubation of poly-
mersomes with encapsulated or free (R)-roscovitine resulted in a
dose-dependent increase in neutrophil apoptosis, but the rate of
apoptosis was not significantly different between these groups
(Fig. 3A). Example dot plots in Fig. 3B demonstrate similar levels
of annexin V–positive and propidium iodide–positive cells were
observed in neutrophils treated with polymersomes compared with
their controls. Empty polymersomes had no effect on neutrophil
viability compared with cells treated with PBS alone (Fig. 3C).
Encapsulated (R)-roscovitine promotes inflammation
resolution in an in vivo Zebrafish model
Previous studies in our laboratory have shown that polymersomes
can improve the delivery of molecules into tissues due to their
intrinsic flexibility (55, 56). For instance, PMPC-PDPA poly-
mersomes have enabled the delivery of fluorescent dextran and
large Igs into ex vivo human skin, the delivery of antibiotics into
human mucosa, and the delivery of small molecules into the
central core of a multicellular tumor spheroid (57, 58). Enhanced
delivery of (R)-roscovitine through the skin may help in the
treatment of inflammatory skin diseases such as psoriasis or severe
eczema.
To study the potential benefits of polymersomes in the treatment
of neutrophil-dominated inflammatory diseases, Zebrafish were
employed as an animal model. Zebrafish provide an excellent
model for studying the innate immune system because the embryos
are transparent and contain neutrophils that can be fluorescently
labeled by transgenesis. Zebrafish neutrophils share morphological,
biochemical, and functional similarity with human neutrophils and
we have shown they respond in a similar manner to chemicals
known to influence neutrophil function (13, 59). Zebrafish tail fin
transection results in sterile inflammation characterized by neu-
trophil recruitment peaking at 6 h postinjury (hpi) and resolution
of neutrophilic inflammation by 24 hpi (33). This provides a rel-
atively cheap, rapid, and effective method for testing the potency
of anti-inflammatory compounds in promoting inflammation res-
olution (13, 59). The transgenic Tg(mpx:GFP)i114 line specif-
ically labels neutrophils with GFP, which allows neutrophils to be
tracked in vivo using a fluorescence microscope (33). To study
polymersome delivery in vivo, 3 dpf mpx:GFP zebrafish embryos
were subject to tail injury by transection of the tail end and in-
cubated with polymersomes encapsulating rhodamine B for 8 h.
Visualization of the tail region by confocal microscopy revealed a
diffuse rhodamine signal throughout the tail (Fig. 4A).
To compare the ability of encapsulated and free (R)-roscovitine
to promote inflammation resolution in vivo, mpx:GFP zebrafish
were injured by tail fin transection and treated at 4 hpi with 30 mM
free (R)-roscovitine, 30 mM of polymersome-encapsulated (R)-
roscovitine, or their respective controls. At 12 hpi the neutrophils
at the site of injury were counted under a fluorescence microscope.
As shown in Fig. 4B, polymersome-encapsulated (R)-roscovitine
significantly reduced the number of neutrophils at the site of injury
at 12 hpi compared with free (R)-roscovitine or control. These results
demonstrate that (R)-roscovitine encapsulated in polymersomes can
speed up inflammation resolution in vivo significantly better than the
free drug.
Discussion
Neutrophils have proven very difficult cells to manipulate, and to
our knowledge no commercially available vector exists that enables
the efficient intracellular delivery of cargo within their short life
span without compromising their viability and activation state. The
ability of PMPC-PDPA polymersomes to deliver cargo into neu-
trophils without detrimental effects may be attributed to a number
of features. It is important to emphasize that most transfection
agents are based on cationic lipids or polymers forming positively
charged nanoparticles that interact strongly with the negatively
charged cell membrane favoring binding and delivery (60). This
strong interaction, however, leads to unspecific binding to TLR,
such as TLR4, with consequent activation of leukocytes (61).
Therefore, it is not surprising that lipoplex, the most-studied non-
viral nucleic acid vector, causes systemic inflammation and tox-
icity when injected into mice (62, 63). Conversely, the neutral
charge of the polymersome membrane prevents non-specific in-
teractions between polymersomes and proteins. This property,
known as anti-fouling, is crucial for translation of synthetic
polymers into the clinic and is responsible for the proven non-
immunogenicity of PMPC (41).
It is likely that the rapid internalization of polymersomes is
mediated through a high binding affinity for their target receptors. It
has previously been shown that the class B scavenger receptors,
scavenger receptors B1 and B2 (SR-BI/SRBII), and CD36 are
essential for the internalization of PMPC-PDPA polymersomes into
a number of cell types (43). Indeed, CD36 and SR-BI/SRBII are
both expressed by neutrophils, which may explain the fast rate of
polymersome internalization (64, 65).
The accumulation of polymersomes within neutrophils will
depend on both the rate of internalization and the rate of removal.
Incubation of human neutrophils with polymersomes resulted in an
increase in fluorescence followed by a gradual plateau. Interest-
ingly, when the polymersomes were removed from solution, the
fluorescence intensity rapidly declined. This indicates that the
polymer is either degraded or released from the cells over time.
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This may also explain the gradual plateau in fluorescence due to a
balance in polymersome internalization and release. Rapid release
of polymersomes following cargo delivery may be beneficial,
preventing the unnecessary intracellular accumulation of polymer
within the cells, but further work will be necessary to confirm this.
The rate of nanoparticle internalization is dependent on a number
of factors. Internalization can be driven in part simply from the
physical interaction of a nanoparticle with the cell membrane. By
modeling membrane wrapping, the Freund group calculated that
there is an optimal nanoparticle diameter of ∼50–60 nm, which
FIGURE 3. Encapsulated and free (R)-roscovitine promote neutrophil apoptosis. (A) Dose response line graph showing the percentage of apoptotic
neutrophils (annexin V positive) when incubated with increasing concentrations of encapsulated or free (R)-roscovitine for 8 h. Treatment with roscovitine
significantly increased neutrophil apoptosis in both groups but encapsulation within polymersomes did not significantly affect apoptosis rates compared
with free roscovitine (two-way ANOVA, error bars show SEM from four independent experiments, p , 0.0001). (B) Dot plots from flow cytometry of
human neutrophils showing annexin V and propidium iodide staining after 8 h incubation with treatment or controls (GM-CSF at 0.01 mg/ml, (R)-
roscovitine at 30 mM, and PMPC-PDPA polymer at 1.15 mg/ml). (C) Bar graph showing the percentage of apoptotic neutrophils (annexin V positive) after
8 h incubation with PBS, DMSO, or empty polymersomes. Treatment with empty polymersomes did not significantly alter the rate of apoptosis (GM-CSF at
0.01 mg/ml, PMPC-PDPA polymer at 1.15 mg/ml) (one-way ANOVA, error bars = SEM from four independent experiments).
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facilitates membrane wrapping in the shortest time period
(49). However, the rate of internalization experimentally varies
depending on the binding affinity and the properties of the
nanoparticle and its target cell (66–70).
In this study, polymersomes with a diameter of ∼190 nm
resulted in the greatest increase in neutrophil fluorescence inten-
sity both when considering the fluorescence from the rhodamine-
labeled polymer and encapsulated cascade blue. It should be
emphasized that the increase in neutrophil fluorescence intensity
from the rhodamine demonstrates that 190 nm polymersomes are
most efficient in terms of the amount of polymer delivered into the
cells, but not the number of polymersomes internalized. This is
because the larger polymersomes are formed from a greater
amount of polymer, and hence more rhodamine is delivered into
the neutrophil for every polymersome that is internalized. How-
ever, the data highlight that this size of polymersome may be
optimal as a drug-delivery vehicle for neutrophils.
The rate of polymersome internalization into FaDu cells com-
pared with neutrophils cannot be compared by fluorescence in-
tensity alone. However, these data show that FaDu cells, unlike
neutrophils, appeared to internalize polymersomes at a similar rate
at all sizes tested. The reason for this is unclear, but may be a result
of the different density of receptors on their cell membrane. Al-
ternatively, the specialized abilities of neutrophils to internalize
larger foreign particles may improve their uptake of polymersomes
with larger diameters. These data suggest that size will influence
the amount of polymersomes that are internalized into neutrophils
compared with other cells. When targeting neutrophils, polymer-
somes with a diameter of ∼200 nm may be effective, whereas a
smaller diameter of ∼50 nm may allow a greater degree of in-
ternalization by cancer cells. (R)-roscovitine encapsulated in
polymersomes promoted neutrophil apoptosis in vitro in a dose-
dependent manner. The ability of encapsulated (R)-roscovitine to
promote neutrophil apoptosis was not significantly different to that
of free (R)-roscovitine. This suggests the mass of (R)-roscovitine
delivered into neutrophils using polymersomes is similar to the
mass of free (R)-roscovitine that enters cells by other means.
Zebrafish provide an excellent model for studying the innate
immune system. The transparent embryos contain neutrophils and
macrophages, which can be fluorescently labeled by transgenesis,
and by 3 dpf the innate immune system is fully functional, allowing
its role in infection and inflammation to be understood in the absence
of the adaptive immune system that does not fully mature until 1 mo
postfertilization (71). The zebrafish has been helpful in the study of
neutrophil biology, leading to a number of discoveries in the field,
including the role of neutrophil reverse migration in inflammation
resolution (34, 72, 73). Using the zebrafish tail transection model, it
was shown that (R)-roscovitine encapsulated within polymersomes
promoted inflammation resolution much more quickly than the free
drug. Free (R)-roscovitine alone did not significantly reduce neu-
trophil numbers at the injury site compared with the untreated
control, although the mean number of neutrophils was slightly
lower (not significant). The improvement of encapsulated (R)-
roscovitine compared with the free drug suggests that polymer-
somes were more efficient at delivering the drug into zebrafish
neutrophils than could be achieved by other means.
Fig. 4 demonstrates that polymersomes are capable of pene-
trating deep into the zebrafish tail. Free (R)-roscovitine will likely
offer only modest tissue penetration because it has a partition
coefficient (logP) of 3.2 and generally only highly hydrophobic
FIGURE 4. Polymersome-mediated de-
livery of (R)-roscovitine into the zebrafish
tail speeds up inflammation resolution.
Zebrafish embryos (mpx:GFP) 3 dpf were
subject to tail injury by transection of the tail
end. (A) At 4 hpi zebrafish embryos were
incubated with polymersomes encapsulating
rhodamine B octadecyl ester perchlorate
(CelLuminate) for 8 h before the fish were
washed and imaged by confocal microscopy.
Original magnification 310. (B) Zebrafish
embryos were treated with 30 mM free or
encapsulated (R)-roscovitine at 4 hpi. At 12
hpi neutrophils numbers at the injury site
were counted using a dissecting microscope.
Encapsulated (R)-roscovitine significantly
improved inflammation resolution compared
with free roscovitine or controls (one-way
ANOVA with Bonferroni post hoc compari-
son, lines represent the mean 6 SEM from
three independent experiments, ***p ,
0.001, ****p , 0.0001).
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molecules are capable of deep tissue penetration; indeed, com-
pounds with a logP below 3.8 have relatively low penetration in
zebrafish (74). Delivery of (R)-roscovitine using polymersomes
helps improve drug tissue penetration and may offer a more se-
lective uptake into immune cells, compared with other cell types
(43, 57, 58). Consequently we believe the superior ability of poly-
mersomes to deliver (R)-roscovitine to neutrophils in the zebrafish
tail improved the outcome of this model. Polymersomes may prove
an effective vector for the local delivery of drugs to neutrophils.
Neutrophil-dominated inflammatory diseases are common and
there are currently no neutrophil-targeted treatments available. In
this study we have shown that PMPC-PDPA polymersomes can
effectively deliver molecules into human neutrophils without
evoking obvious detrimental effects on neutrophil viability or IL-8
release. These polymersomes successfully encapsulated and de-
livered (R)-roscovitine to promote neutrophil apoptosis in vitro and
help resolve a model of neutrophilic inflammation in vivo. These
results have important consequences for the study of neutrophil
biology, and the development of neutrophil-targeted therapeutics.
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